Literature DB >> 2471813

Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.

R H Meloen1, R M Liskamp, J Goudsmit.   

Abstract

An important antigenic determinant of human immunodeficiency virus type 1 that induces neutralizing activity in infected humans and chimpanzees was previously mapped with nonapeptides between amino acids 307 and 320 on the external envelope glycoprotein (gp 120) of strain HTLV-IIIB (molecular clone BH10) and amino acids 320 to 330 of strain HTLV-IIIRF. Using different sera we found different reactive nonapeptides that overlapped and shared a tetrapeptide, GPGR. This tetrapeptide, which is the same in HTLV-IIIB and HTLV-IIIRF, is flanked by amino acids that vary between virus strains. Because GPGR is predicted to form a beta-turn and is flanked by two cysteine residues that may form a disulphide bridge, a hairpin-like structure is suggested for this part of gp120. The tetrapeptide GPGR and the reactive peptides are located on top of this structure, well exposed to antibodies. We determined the role of the individual amino acids in antibody binding using three sets of peptide analogues derived from three reactive nonapeptides (two of strain HTLV-IIIB which overlapped and one of strain HTLV-IIIRF). Each set contained peptide analogues in which each amino acid was replaced, one at a time, by all genetically encoded amino acids. At least five consecutive amino acids in each nonapeptide were essential for antibody binding. They include amino acids of GPGR and potentially provide the virus with ample opportunity to escape immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471813     DOI: 10.1099/0022-1317-70-6-1505

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Effect of core epitope modification on the antibody recognition of a MUC2 mucin peptide.

Authors:  Katalin Uray; Ferenc Hudecz
Journal:  Mol Divers       Date:  2012-03-04       Impact factor: 2.943

4.  Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.

Authors:  C H Chen; L Jin; C Zhu; S Holz-Smith; T J Matthews
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.

Authors:  P Simmonds; P Balfe; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J F Dedieu; J Ronco; S van der Werf; J M Hogle; Y Henin; M Girard
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.